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Abstract 
 
Purpose: Stereotactic radiosurgery (SRS) is typically considered for patients who are unable to undergo surgical 
resection for large (> 10 cm
3
) brain metastases (BMs). While staged SRS requires adaptive planning during each 
stage of the irradiation period to improve tumor control and reduce radiation damage, no studies have previously 
evaluated tumor reduction rates using this method. We evaluated the outcomes of 2-stage SRS according to 
primary cancer type. 
Methods: We analyzed 178 patients with 182 large BMs initially treated with 2-stage SRS  Primary cancers 
included breast (BC), non-small cell lung (NSCLC), and gastrointestinal tract cancers (GIC). We analyzed 
overall survival (OS), neurological death, systemic death (SD), tumor progression (TP), tumor recurrence (TR), 
radiation necrosis (RN), and the tumor reduction rate during both sessions. 
Results: Median survival time after the first Gamma Knife surgery (GKS) procedure was 6.6 months. OS was 
shorter, and SD incidences were higher in patients with GIC than those with BC and NSCLC. Tumor reduction 
rate was significantly higher in patients with BC than in those with NSCLC and GIC. TP rates were similar 
among primary cancer types. Tumor reduction rate was not associated with tumor control. The overall 
cumulative incidence of RN was 4.2% and RN rates were similar among primary cancer types. 
Conclusions: Two-stage SRS should be considered for BC and NSCLC if surgical resection is not indicated. 
For BMs from GIC, staged SRS might be carefully considered and adapted depending on the case, considering 
the lower tumor reduction rate and shorter OS. 
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Introduction 
 Approximately 20–40% of patients with cancer develop brain metastases (BMs) [1]. Local control 
of BMs has become a critical issue since the evolution of chemotherapy, and molecular targeting drugs, immune 
checkpoint inhibitors, and radiotherapy have improved the life expectancy of cancer patients. Large BMs (> 10 
cm
3
) can typically be treated with surgery and/or whole brain radiation therapy (WBRT) [2-7]. However, the 
selection of patients for operative intervention is limited by age, Karnofsky Performance Status (KPS), tumor 
location, extracranial disease status, and patient preference [8]. Tumor size is negatively correlated with the 
tumor control rate [31] and positively correlated with the risk of neurotoxicity. The prescribed dose should 
decrease for larger BMs; however, low prescribed doses (< 15Gy) are associated with poor outcomes [16]. In 
patients with large BMs who cannot undergo craniotomy or WBRT, tumor control and radiation damage are 
challenging. In these cases, stereotactic radiosurgery (SRS) is an effective option [5, 9-13]. Meanwhile, SRS by 
Gamma Knife limits the indication for treatment according to the volume of the metastatic tumors [14-16]. 
Recently, staged SRS has been developed to deliver a sufficient prescribed radiation dose while 
reducing the risk of neurotoxicity, and its effectiveness has been reported [17-24]. Both 3-stage and 2-stage SRS 
have been reported, and there was no difference in the outcomes [23]. In staged SRS, tumor volume is 
calculated for adaptive planning at the time of second fractions. This leads to a reduction of prescription volume, 
and reduced neurotoxicity. 
To the best of our knowledge, tumor reduction rates achieved with staged SRS have not yet been 
reported according to the primary cancer type. In this study, we aimed to clarify the role of staged SRS in cancer 
treatment, focusing on tumor volume reduction rate and tumor control, and compared the effectiveness 
according to primary cancer type, with a view to suggesting appropriate treatment strategies. 
 
Methods 
Patient population 
 The institutional review board of Chiba Cerebral and Cardiovascular Center IRB (IRB number: 
#456) approved this retrospective study. The major eligibility criteria were as follows: 1) newly diagnosed BMs, 
2) tumor volume > 10 cm
3
, 3) primary cancer was BC, non-small cell lung cancer (NSCLC), or GIC. We 
enrolled 178 patients with 182 lesions treated with 2-stage SRS between April 2008 and March 2019 at Chiba 
Cerebral and Cardiovascular Center and Tsukiji Neurological Clinic. In all patients, a Leksell G frame (Elekta 
Instrument, Stockholm, Sweden) was secured with screw pins under local anesthesia with adequate sedation, as 
necessary. For each dose planning, gadolinium (Gd)-enhanced T1-weighted magnetic resonance (MR) images 
were obtained. Neither the Extend system with Perfexion nor the mask system with ICON was used in this 
series. No margins were set for the gross, clinical, or planning target volumes. All patients underwent staged 
SRS alone, not in combination with concurrent WBRT. 
  
Definition of clinical outcomes 
 Overall survival (OS) was defined as the interval between the first SRS procedure and death. Tumor 
progression was defined as a 20% increase in the maximum diameter of the Gd-enhanced lesion since the first 
SRS [23, 30]. Neurologic death (ND) was defined as death by intracranial disease progression, such as tumor 
recurrence, or leptomeningeal and cerebral dissemination. Systemic death was defined as death due to primary 
lesion progression. Tumor recurrence (TR) and radiation necrosis (RN) were judged by various imaging 
findings on MR imaging, MR spectroscopy, single-photon emission computed tomography, positron emission 
tomography, and clinical course. The reduction rate was calculated from the difference in the tumor volume, 
measured by Gamma Plan
TM
, at the first and second SRS. 
 
Statistical analysis 
 Patient characteristics related to sex, age at diagnosis, primary cancer, KPS score, tumor volume, 
prescribed dose, duration between first and second SRS were obtained, using median values for continuous 
factors and percentages for categorical factors. OS was estimated by the Kaplan–Meier method. Tumor control, 
including TP and TR, was calculated by Gray analysis taking competing risk into consideration. We accounted 
for death as a competing risk for TP, death or RN as a risk for TR, and death or TR as a risk for RN. The 
reduction rate was analyzed by one-way analysis of variance. All statistical analyses were performed using EZR 
version 1.40 (Saitama Medical Center, Jichii Medical university). A p-value < 0.05 was considered statistically 
significant.  
 
Results 
Patient characteristics 
 Clinical characteristics were compared among primary cancer types, and are shown in Table 1. In 
patients with GIC, KPS scores were significantly worse (p = 0.001), neurological symptoms more frequent (p = 
0.022), and modified recursive partitioning analysis classes [25] worse (p = 0.0001) than in patients with BC 
and NSCLC. Age, extracranial disease status, including systemic disease status and extracranial metastases, 
tumor volume, prescribed dose, and duration from first to second Gamma Knife surgery (GKS) procedure were 
not significantly different among three primary cancer types.  
 
Clinical outcomes 
 Comparison of clinical outcomes among primary cancer types is shown in Table 2. The median 
follow-up duration after the first GKS procedure for the 178 cases was 5.4 months (range: 2.5–12.4 months). 
The MST after the first GKS procedure was 6.6 months. The OS since the first GKS differed among the primary 
cancer types (Fig. 1A, p = 0.002). Patients with GIC showed a significantly higher rate of systemic death 
compared with those with BC and NSCLC (p = 0.002). A total of 141 patients (79.8%) had died by the time of 
the final data analysis; among these, 20 were associated with ND, 8 with BC, 3 with GIC, and 9 with lung 
cancer. The cumulative incidence of ND was 11.2% in patients overall. The causes of ND were classified as 
carcinomatous meningitis in 10 (50.0%), recurrence of the GKS-treated lesion in 8 (40.0%), and progression of 
the untreated lesion in 2 (10.0%).  
 
Tumor control  
 Thirty-three patients (18.5%) were associated with TP, 8 with BC, 10 with GIC, and 15 with lung 
cancer. Among the 33 patients with TP, 19, 11, 2, and 1 underwent repeated SRS, observation, surgical removal, 
and WBRT, respectively. The cumulative incidence of TP was 6.8% in patients overall, 0.0% in BC, 14.3% in 
GIC, and 6.0% in NSCLC patients at 6 months after the first GKS procedure. The rate of TP was not 
significantly different among the three primary cancer types. No cases were diagnosed as mixed/undetermined 
lesions. Twenty-two patients (12.4%) were associated with TR, 7 with BC, 6 with GIC, and 9 with lung cancer. 
The cumulative incidence of TR was 2.5% in patients overall at 6 months after the first GKS procedure. The TR 
rate did not differ significantly among the primary cancer types (Table 2). 
The cumulative RN incidence was 4.2% in patients overall. The RN rate was not significantly different among 
the three primary cancers. RN occurred in 11 patients (6.2%): 1 patient with BC, 4 patients with GIC, and 6 
patients with lung cancer. Among the 11 patients with RN, 3, 5, and 3 patients demonstrated Common 
Terminology Criteria for Adverse Events grade 3 toxicity, grade 2 toxicity and grade 1 toxicity, respectively. 
There was no relationship between the reduction rate and RN rate. 
 
Tumor volume reduction during the treatment protocol 
 The median tumor volume reduction rate with the second GKS procedure was 26.6% (interquartile 
range; IQR: 7.4–44.8%) in patients overall, 46.1% (IQR: 14.1–68.8%) in BC, 18.2% (IQR: 3.4–37.0%) in GIC, 
and 26.6% (IQR: 7.2–38.3%) in NSCLC. The tumor volume reduction rate differed significantly among the 
primary cancer types (p = 0.002) (Fig1-B). Tumor reduction rate was significantly higher in patients with BC 
than in those with NSCLC and GIC. Forty lesions showed volume decreases of < 5% with the second GKS 
procedure. The primary pathologies of these 40 low-responders were BC in 5 (13.5%), GIC in 12 (24.5%), and 
NSCLC in 23 (24.0%); these rates differed significantly (p = 0.011). In the low-responders, we observed TP in 7 
lesions, TR in 4 lesions and RN in 3 lesions. ND occurred due to carcinomatous meningitis in 1 and recurrence 
of the GKS-treated lesion in 2 patients.  
 
Prognostic factors for clinical outcomes 
 The proportion hazards model for OS is shown in Table 3. A low KPS score (< 60), active 
extracranial disease status, GIC, and large tumor volume (> 20 cm
3
) were identified as unfavorable prognostic 
factors that independently predicted OS rates. The proportion hazards model for TR is shown in Table 4. Older 
age (> 65-years old) was identified as a favorable prognostic factor independently predicting TR rate. 
Therapeutic factors, such as the duration between the first and second GKS or the prescribed dose were not 
identified as prognostic factors predicting either tumor progression or TR. 
 
Discussion 
 In this study, we assessed 2-stage SRS as a strategy for treating large (> 10 cm
3
) BMs by comparing 
the clinical outcomes among different primary cancers; we compared tumor volume reduction rate in the short 
term, tumor control in the long term, as well as the relationship between tumor volume reduction and tumor 
control. We found that patients with GIC had a shorter OS than patients with BC and NSCLC. BMs from BC 
showed a higher tumor volume reduction rate than those arising from GIC. There was no correlation between 
tumor reduction rate and tumor control. Additionally, patients under 65-years old showed a higher incidence in 
local recurrence than older patients. A study by Serizawa et al. included 1194 patients who had 2–10 BMs 
treated by SRS. They reported 4 clinical factors that impacted local tumor progression using the Fine-Gray 
proportional hazards model [30]. These poor prognostic factors were 1) patients under the age of 65 years, 2) 
patients with neurological symptoms, 3) patients with larger tumor volumes, and 4) a low prescription dose (< 
22Gy) [30]. In our study, we introduced a competing analysis method to evaluate local recurrence. We 
accounted for death as a competing risk for TR. The OS of the elderly was significantly shorter than that in 
younger patients, which may affect the finding that younger patients showed higher local recurrence than older 
patients. The period from the date of primary cancers diagnosis to delivery of the first SRS fraction was 78.2 
months ± 220.7 months in patients over 65-years old, and 28.3 ± 29.1 months (p = 0.07) in patients under 
65-years old. This showed a trend for a shorter period in patients under 65-years old.  
 
 
Consideration of the primary cancers affecting OS and tumor control 
 The median survival time (MST) was the longest in patients with BC (7.0 months), and was the 
shortest (5.3 months) in patients with GIC. This result was consistent with a previous study by Nieder et al. In 
their diagnosis-specific graded prognostic assessment study of 412 patients with brain metastases, many patients 
were treated with surgical resection or SRS, and the overall median survival was 3.6 months from the first day 
of treatment [26]. The primary tumor type was associated with survival. The MST of patients with BC was most 
favorable (9.0 months), and that of patients with GIC was least favorable (5.3 months). Furthermore, in our 
study, the primary cancer type did not affect tumor control. In other words, in patients with BMs from GIC, with 
a short OS, intracranial metastases were controlled to the same extent as those in patients with BMs from BC, 
with a long OS. Despite control of intracranial metastases, the OS is short in patients with BMs arising from 
GIC, suggesting that the survival prognosis is likely dependent on the progression of extracranial lesions in 
these patients. 
 
Consideration of the tumor reduction rate according to primary cancers and the relationship between tumor 
reduction rate and tumor control 
 Small cell lung cancer, lymphoma, and germ cell tumors are regarded as highly radiosensitive 
tumors, while malignant melanoma, renal cell carcinoma, and sarcoma are regarded as radioresistant tumors [27 
28]. NSCLC, BC, and GIC are regarded as intermediate radiosensitive tumors. In our study, we targeted these 
intermediate radiosensitive tumors. To the best of our knowledge, no previous study compared the tumor 
reduction rate and tumor control between different tumor groups involving moderately radiosensitive tumors. 
Higuchi et al. have reported the efficacy and safety of staged SRS for the treatment of large BMs [17]. Their 
subjects included 43 patients who had large BMs (> 10 cm
3
) treated by 3-stage SRS without WBRT. The 
peripheral dose was 10 Gy and the interval between fractions was 2 weeks. According to their study, the mean 
tumor volume decreased by 18.8% with the second fraction. However, they did not report a difference in the 
tumor volume reduction rate among primary cancer types. In our study, the mean tumor volume decreased by 
26.6% with the second fraction. We speculate that the difference in tumor volume reduction rate between our 
study and that of Higuchi et al. could be due to the difference in the treatment interval, prescribed dose, and 
patient characteristics. In our study, large BMs from BC showed significantly greater volume reduction than 
those from GIC and NSCLC. 
 A previous study demonstrated that the tumor volume reduction rate was related to tumor control 
[19]. Their treatment interval was longer than that in our study, and the reduction rate evaluation interval was 
longer accordingly. The treatment interval is a factor that affects tumor reduction rate; this may underlie the 
difference between the findings of the previous and our present study. On the other hand, some cancers show 
high radiosensitivity, but poor tumor control, such as small cell lung cancer [27, 28] Adenocarcinoma is known 
to show a slow radiation response [29]. Thus, it is possible that there is no relationship between the reduction 
rate and tumor control. Staged SRS was developed to reduce the radiation prescription volume and radiation 
toxicity by re-planning the irradiation range according to short-term tumor shrinkage for large BMs [17]. 
However, there are still few reports on the reduction rate and tumor control with staged SRS, and additional 
cases should be accumulated in future studies. We have discussed the relationship between tumor control and 
OS, as is the convention in such studies. However, a previous study has reported that tumor reduction 
contributes to improved KPS [19]. Because the improvement of KPS may expand treatment options, the 
relationship between tumor reduction, tumor control, and OS should also be considered in future studies. 
 
 
Consideration of treatment strategy for patients with large BMs by SRS 
 It is recommended that BMs with a diameter exceeding 3 cm be surgically excised and/or treated 
with WBRT or SRS [6,7]. Surgery should be performed if the patient is young, has a tumor in a non-eloquent 
area, shows a good KPS, and has no active extracranial lesions, for any primary cancer type. However, in some 
cases, it is challenging to select surgery, due to the patient’s age, localization of the tumor in an eloquent area, 
the patient’s poor general condition, presence of active extracranial lesions, and patient preference. In these 
cases, particularly for patients who have large BMs arising from BC and NSCLC, staged SRS may be a 
treatment option and provide short-term tumor reduction and improvement of the KPS. On the other hand, for 
patients who have large BMs arising from GIC, it is difficult to expect a significant tumor reduction, and the 
progression of extracranial lesions is likely to cause death within a relatively short period. In these cases, we 
may have to carefully consider the adaptation of staged SRS. 
 
Limitations and prospects 
 This study had some limitations. All patients in this study were treated with 2-stage SRS as the 
initial therapy for large BMs. Despite advances in oncologic therapies, we could not analyze the effect of gene 
mutation or novel oncologic therapies, including molecular targeting drugs, as such information was not 
available for the patients involved in this study. The maximum volume treatable by SRS, optimal interfraction 
interval and prescribed dose are still controversial. Further prospective study with more information on gene 
mutation and detailed oncologic therapies will be required.  
 
Conclusion 
 To the best of our knowledge, this is the first study to report the tumor reduction rate among primary 
cancers after 2-stage SRS in a large number of patients. In this study, tumor reduction rate was not a prognostic 
factor for tumor control. In patients with large BMs due to BC, staged SRS can be expected to reduce tumor size. 
In patients with large BMs from NSCLC, staged SRS can be expected to improve OS and tumor control, similar 
to BC; therefore, staged SRS can be considered. In patients with large BMs from GIC, 2-stage SRS might be 
carefully considered, as these patients show a lower tumor reduction rate and shorter OS.  
  
Figure Captions 
 
Fig. 1A Kaplan–Meier curves showing overall survival of patients with different primary cancers 
The median survival time of all patients was 6.6 months (95% CI: 5.3–9.3). The median survival time of 
patients with BC, NSCLC, and GIC was 8.9 months (95% CI: 5.4–15.0), 9.3 months (95% CI: 4.5–11.1), and 
5.2 months (95% CI: 3.5–5.8), respectively. The overall 6- and 12-month OS rates after the first SRS were 52% 
and 33%, respectively, and 57.1% and 42.9%, 59.3% and 36.8%, and 33.4% and 15.9%, respectively, in patients 
with BC, NSCLC, and GIC 
 Fig. 1B The reduction rate was analyzed by one-way analysis of variance 
The median tumor volume reduction rate was 46.1% in BC, 18.2% in GIC, and 26.6% in NSCLC. BMs from 
BC showed significantly higher rate of reduction compared with those with GIC (p=0.001) and NSCLC 
(p=0.007). 
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